The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
== Properties == The alcohol dehydrogenases comprise a group of several isozymes that catalyse the oxidation of primary and secondary alcohols to aldehydes and ketones, respectively, and also can catalyse the reverse reaction. In mammals this is a redox (reduction/oxidation) reaction involving the coenzyme nicotinamide adenine dinucleotide (NAD+).
Prior to the outbreak of the civil war in 1991, the roughly 53 state-owned small, medium and large manufacturing firms were foundering, with the ensuing conflict destroying many of the remaining industries. However, primarily as a result of substantial local investment by the Somali diaspora, many of these small-scale plants have reopened and newer ones have been created. The latter include fish-canning and meat-processing plants in the northern regions, as well as about 25 factories in the Mogadishu area, which manufacture pasta, mineral water, confections, plastic bags, fabric, hides and skins, detergent and soap, aluminium, foam mattresses and pillows, fishing boats, carry out packaging, and stone processing. In 2004, a US$8.3 million Coca-Cola bottling plant also opened in the city, with investors hailing from various constituencies in Somalia. Foreign investment also included multinationals including General Motors and Dole Fruit.
Those who eat it have visions of fearful things. Magicians or those who wish to harm someone administer it in food or drink. This herb is medicinal and its seed is used as a remedy for gout, ground up and applied to the part affected." Christian Rätsch has said, "A mild dosage produces medicinal and healing effects, a moderate dosage produces aphrodisiac effects, and high dosages are used for shamanic purposes". Wade Davis, an ethnobotanist, also lists it as an essential ingredient of a zombie potion in Haitian Vodou. In Western culture, the same species (Datura stramonium) has been said to have been commonly used by witches as an ingredient for their flying ointments and was regularly included in detailed recipes of magical ointments dating back as far as the early modern period, predominately in New England and Western Europe. During the anti-witchcraft hysteria of colonial times it was considered unlucky or inappropriate to grow D. stramonium in one's garden due to its supposed reputation for aiding in incantations.
== History == Modafinil was developed in France by neurophysiology professor Michel Jouvet and Lafon Laboratories in the 1970s. Modafinil is the primary metabolite of adrafinil, an earlier compound in the benzhydryl sulfinyl series. Modafinil has been prescribed in France since 1994 under the name Modiodal, and in the United States since 1998 as Provigil. The US Food and Drug Administration approved modafinil in 1998 for narcolepsy treatment, and later for shift work sleep disorder and obstructive sleep apnea in 2003. It was approved in the UK in December 2002. In the United States, modafinil is marketed by Cephalon, a biopharmaceutical company acquired by Teva Pharmaceutical Industries in 2011, who acquired the rights from Lafon and purchased the company in 2001. Cephalon introduced armodafinil, the (R)-enantiomer of modafinil, in the United States in 2007. Generic versions of modafinil became available in the US in 2012 after extensive patent litigation.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}[][a_{0},a_{1},a_{2},a_{3}]&=[0.616634218997,0.108855827811,0.023453835635,0.000449332509]\\[][b_{1},b_{2},b_{3},b_{4},b_{5},b_{6}]&=[1.919948267476,1.635304362591,0.799392556572,0.240278859212,0.043178653945,0.003863334276]\end{aligned}}}
=== Debate over Mercury project continuation === The Mercury-Atlas 8 flight of Walter Schirra on October 3, 1962, had been so nearly perfect that some at NASA thought that the United States should quit while it was ahead and make MA-8 the last Mercury mission rather than risk a future disaster. The argument that MA-8 should be the last Mercury mission held that NASA had pushed the first-generation Mercury hardware far enough, and taking more chances on another longer mission was not warranted; instead, NASA should move on to the Gemini program. Manned Spacecraft Center officials, however, believed that the Mercury team should be given the chance to test a human in space for a full day. In addition, all of the Soviet single-seat Vostok spacecraft launched after Vostok 1 lasted for more than a day; thus the Mercury 9 flight would bring the Mercury spacecraft up to the same level as that of the Soviets.
== Remission == Remission occurs when a cat no longer requires treatment for diabetes and has normal blood glucose concentrations for at least a month. Approximately one in four cats with type 2-like diabetes achieves remission. Some studies have reported a higher remission rate than this, which may in part be due to intensive monitoring that is impractical outside of a research environment. Research studies have implicated a variety of factors in successful remission; in general, the following factors increase the likelihood of remission:
=== Ryan Crowley === Ryan Crowley was drafted to the Fremantle Football Club in 2002 and played his first AFL game in 2005. He tested positive to a banned substance on match day in the season of 2014. The banned substance was in a painkiller, known as methadone, that he had taken two pills of prior to the game due to back pain. This was not prescribed by the club doctor. He was given a 12-month ban from playing in the AFL but still trained with his team. He became able to play on 25 September 2015, and after being delisted by Fremantle at season's end, joined Essendon as a top-up player due to the club's supplements saga.
The administration has left financing for eradication projects in the Andes largely unchanged, despite debate over whether such efforts can sharply restrict the supply of cocaine or significantly increase the price in the United States in the long run. American anti-narcotics aid for Peru stands at $71.7 million this year, slightly higher than last year's $70.7 million. American anti-narcotics officials operate from a newly expanded Peruvian police base in Tingo María, overseeing Peruvian teams that fan out to nearby valleys to cut down coca bushes by hand.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.